北京依生兴业科技有限公司 Yisheng Pharma
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
YS Biopharma Announces Appointment of New Directors 2024-02-14 20:50
YS Biopharma Announces US$40 Million Private Placement Financing 2024-02-09 19:30
YS Biopharma Announces Unaudited Financial Results for the First Half of Fiscal Year 2024 2024-01-23 06:00
YS Biopharma Announces Changes to its Board Committees 2024-01-08 21:00
YS Biopharma Responds to Unauthorized Press Release Regarding Extraordinary General Meeting 2023-12-21 05:30
/DISREGARD RELEASE: YS Biopharma/ 2023-12-21 05:15
Noble Capital Markets Initiates Coverage on YS Biopharma With Outperform Rating and US$5.25 Price Target 2023-11-14 21:30
YS Biopharma Announces Completion of Subject Enrollment in Pivotal Phase 3 Clinical Trial of PIKA Rabies Vaccine 2023-10-31 20:30
YS Biopharma Announces Receipt of Nasdaq Notice 2023-10-26 20:30
YS Biopharma Announces First Subject Enrollment in Pivotal Phase 3 Clinical Trial of PIKA Rabies Vaccine 2023-09-26 20:30
YS Biopharma Granted Patent in the U.S. for Immunotherapy Targeting Chronic Hepatitis B Virus Infection 2023-09-15 20:30
YS Biopharma to Participate in Citi's 18th Annual Biopharma Conference 2023-09-05 20:30
YS Biopharma Announces Purchase of Shares by Company Officers 2023-08-25 04:15
YS Biopharma Announces Unaudited Financial Results for the First Quarter of Fiscal Year 2024 2023-08-16 05:00
YS Biopharma Announces Unaudited Financial Results for the First Quarter of Fiscal Year 2024 2023-08-16 05:00
YS Biopharma to Report First Quarter Fiscal Year 2024 Financial Results on August 15, 2023 2023-08-11 04:30
YS Biopharma Announces Financial Results for Fiscal Year 2023 Ended March 31, 2023 2023-07-27 05:00
YS Biopharma to Report Financial Results for Fiscal Year 2023 on July 26, 2023 2023-07-22 04:30
YS Biopharma to Report Financial Results for Fiscal Year 2023 on July 26, 2023 2023-07-22 04:30
YS Biopharma's PIKA Rabies Vaccine Receives Phase 3 Clinical Trial Approval From Philippines FDA 2023-06-01 20:30
1 2 3 4